Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene in Patients With NSCLC
This is a phase II, single institution trial to correlate gefitinib response and mutations
in the protein-tyrosine kinase domain of the EGF receptor gene. The study will be conducted
in patients with Stage I and II NSCLC who have been determined to be operable and
resectable.
Patients must have 1 or more of the following features: never smoker or smoking history of <
15 pack years and/or features of bronchioloalveolar lung cancer. 50 patients will be
enrolled on this study. Treatment will be with gefitinib for at least 21 days before surgery
(depending on the timing of the surgery). Patients will discontinue gefitinib 2 days before
their operation. For patients that demonstrate a radiographic response to gefitinib
preoperatively and /or patients with mutations in the protein-tyrosine kinase domain of the
EGF receptor gene (identified from the surgical sample), gefitinib will continue for 2 years
post-surgery. Patients who do not have evidence of radiographic response or mutations in the
protein-tyrosine kinase domain of the EGF receptor gene will be removed from the study.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To correlate the radiographic response to gefitinib with the presence of mutations in the protein-tyrosine kinase domain of the EGF receptor gene in tumor specimens obtained before treatment with gefitinib.
2 years
Yes
Naiyer Rizvi, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
04-071
NCT00588445
June 2004
September 2010
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |